Is Descovy really the better option?
When the FDA approved Gilead’s Truvada (emtricitabine/tenofovir disoproxil) for HIV PrEP in 2012, it was a revolutionary step forward. The drug was safe and up to 99 percent effective in preventing HIV infection in at-risk individuals.
Then in 2019, Gilead received FDA approval for a second drug for PrEP called Descovy (emtricitabine/tenofovir alafenamide), with equivalent efficacy to Truvada. Recent research has shown that by the end of 2020, …









![Medical brain drain leaves vulnerable communities without life-saving care [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-1-190x100.jpg)
![Collaborative partnerships save rural health care from collapse [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-3-190x100.jpg)

